好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Shifts in Mortality in Individuals with Dementia and Chronic Kidney Disease: Insights from the CDC WONDER Database Over Two Decades
Aging, Dementia, and Behavioral Neurology
P9 - Poster Session 9 (5:00 PM-6:00 PM)
12-012
To evaluate the temporal trends and overlap between dementia and chronic kidney disease (CKD) related co-mortality from 1999 to 2023 in the United States.
Dementia and CKD are highly prevalent in the United States (US) population, and often cooccur. Mortality trends related to dementia and CKD in the US population are unknown. 
We analyzed the age-adjusted mortality rates (AAMR) in individuals with dementia and CKD captured within the Centre for Disease Control and Prevention WONDER database—a publicly-available population-based database that provides nationwide death certificate information and underlying causes of death. We used the “Multiple Cause of-Death” ICD-10 codes. Temporal trends were plotted, and annual percentage change (APC) calculated using the joinpoint regression models. We further assessed the association between mortality trends and sex, race, and age.
21,8981 deaths were reported in individuals with dementia and CKD from 1999-2023; 98.6% of individuals were ≥65-years-old at death. The AAMR increased from 1999-2012 (APC: +12.6%; 95% CI: 2.6–22.9), decreased from 2012-2015 (APC: -13%; 95% CI: -20.9–-22.9); and increased again from 2015-2023 (APC: +6.2%; 95% CI: 0.9–18.9). AAMR were higher in males (AAMR 2.87; p < 0.001) than females (AAMR: 2.24; p <0.001), and in Black (AAMR: 4.12; p < 0.001) versus White (AAMR: 2.3; p < 0.001) and Asian/Pacific Islander Americans (AAMR: 2.6; p < 0.001). The highest burden of co-mortality was observed in people living in the Midwest (AAMR: 2.71; p < 0.001), followed by South (AAMR: 2.58; p < 0.001) and West (AAMR: 2.57; p < 0.001) regions of the United States. 
Mortality rates attributed to dementia and CKD are increasing among older Americans, with disproportionate effects experienced by males and Black Americans. 
Authors/Disclosures
Anas M. Elgenidi, MD
PRESENTER 		Dr. Elgenidi has nothing to disclose.
LaTonya Hickson, MD Dr. Hickson has received personal compensation for serving as an employee of Mayo Clinic. Dr. Hickson has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for National Institute on Aging.
Gregory S. Day, MD, MSc, FAAN (Mayo Clinic) Dr. Day has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Arialys Therapeutics. Dr. Day has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for DynaMed (EBSCO Health). Dr. Day has or had stock in ANI Pharmaceuticals. The institution of Dr. Day has received research support from National Institutes of Health / NIA. The institution of Dr. Day has received research support from National Institutes of Health / NINDS. The institution of Dr. Day has received research support from Amgen Pharmaceuticals. The institution of Dr. Day has received research support from AVID Radiopharmaceuticals. Dr. Day has received personal compensation in the range of $500-$4,999 for serving as a Presenter at Annual Meeting (CME) with 好色先生. Dr. Day has received personal compensation in the range of $500-$4,999 for serving as a Content Development (CME) with PeerView, Inc. Dr. Day has received personal compensation in the range of $5,000-$9,999 for serving as a Content Development (CME) with Continuing 好色先生, Inc. Dr. Day has received personal compensation in the range of $5,000-$9,999 for serving as a Content Development (CME) with Ionis Pharmaceuticals. Dr. Day has received personal compensation in the range of $500-$4,999 for serving as a 好色先生al Case Development + Presentation (video) with PeerDirect (P\S\L Group). Dr. Day has received personal compensation in the range of $500-$4,999 for serving as a Content Development / Presentation (non-CME) with MJH Life Sciences (NeurologyLive). Dr. Day has a non-compensated relationship as a Clinical Director with Anti-NMDA Receptor Encephalitis Foundation that is relevant to AAN interests or activities.